WA
BCRX icon

WFG Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

WFG Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-600
Closed -$7K – 1777
2014
Q4 		$7K Hold
600
– – ﹤0.01% 1558
2014
Q3 		$6K Hold
600
– – ﹤0.01% 1606
2014
Q2 		$8K Hold
600
– – ﹤0.01% 1544
2014
Q1 		$6K Hold
600
– – ﹤0.01% 1575
2013
Q4 		$5K Hold
600
– – ﹤0.01% 1734
2013
Q3 		$4K Hold
600
– – ﹤0.01% 1776
2013
Q2 		$1K Buy
+600
New +$1.03K ﹤0.01% 1927

Other funds holding BCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

WFG Advisors's BCRX Position: Q1 2015 in Review

WFG Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2015, closing a stake of 600 shares — an estimated $7K sold.

WFG Advisors first reported a position in BCRX in Q2 2013 and held it in 7 quarters. The position peaked at $8K in Q2 2014. 98 funds tracked by Wall St. Rank hold BCRX as of Q1 2015.

  • WFG Advisors reported no remaining BioCryst Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • WFG Advisors sold 600 BioCryst Pharmaceuticals shares in Q1 2015, an estimated $7K.
  • WFG Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • WFG Advisors's BioCryst Pharmaceuticals position peaked at $8K in Q2 2014.
  • 98 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2015.

Based on WFG Advisors's 13F filing for Q1 2015, filed 12 May 2015.